@article{Purshouse_K-2020_8927,
title = {COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study},
author = {Purshouse, K. and Lee, L. and Cazier, J. and Angelis, V. and Arnold, R. and Bisht, V. and Campton, N. and Chackathayil, J. and Cheng, V. and Curley, H. and Fittall, M. and Freeman-Mills, L. and Gennatas, S. and Goel, A. and Hartley, S. and Hughes, D. and Kerr, D. and Lee, A. and Lee, R. and McGrath, S. and Middleton, C. and Murugaesu, N. and Newsom-Davies, T. and Okines, A. and Olsson-Brown, A. and Palles, C. and Pan, Y. and Pettengell, R. and Powles, T. and Protheroe, E. and Sharma-Oates, A. and Sivakumar, S. and Smith, A. and Starkey, T. and Turnbull, C. and Várnai, C. and Yousaf, N. and Team, T. and Kerr, R. and Middleton, G.},
month = {jun},
year = {2020},
abstract = {Background: Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer. Methods: In this prospective observational study, all patients with active cancer and presenting to our network of cancer centres were eligible for enrolment into the UK Coronavirus Cancer Monitoring Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time reports to frontline doctors about the effects of COVID-19 on patients with cancer. Eligible patients tested positive for severe acute respiratory syndrome coronavirus 2 on RT-PCR assay from a nose or throat swab. We excluded patients with a radiological or clinical diagnosis of COVID-19, without a positive RT-PCR test. The primary endpoint was all-cause mortality, or discharge from hospital, as assessed by the reporting sites during the patient hospital admission. Findings: From March 18, to April 26, 2020, we analysed 800 patients with a diagnosis of cancer and symptomatic COVID-19. 412 (52%) patients had a mild COVID-19 disease course. 226 (28%) patients died and risk of death was significantly associated with advancing patient age (odds ratio 9·42 [95% CI 6·56–10·02]; p&lt;0·0001), being male (1·67 [1·19–2·34]; p=0·003), and the presence of other comorbidities such as hypertension (1·95 [1·36–2·80]; p&lt;0·001) and cardiovascular disease (2·32 [1·47–3·64]). 281 (35%) patients had received cytotoxic chemotherapy within 4 weeks before testing positive for COVID-19. After adjusting for age, gender, and comorbidities, chemotherapy in the past 4 weeks had no significant effect on mortality from COVID-19 disease, when compared with patients with cancer who had not received recent chemotherapy (1·18 [0·81–1·72]; p=0·380). We found no significant effect on mortality for patients with immunotherapy, hormonal therapy, targeted therapy, radiotherapy use within the past 4 weeks. Interpretation: Mortality from COVID-19 in cancer patients appears to be principally driven by age, gender, and comorbidities. We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other anticancer treatment are at an increased risk of mortality from COVID-19 disease compared with those not on active treatment. Funding: University of Birmingham, University of Oxford.},
pages = {1919-1926},
volume = {395},
issue = {10241},
journal = {The Lancet},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S0140-6736(20)31173-9},
}
